Search

Your search keyword '"Currier JR"' showing total 122 results

Search Constraints

Start Over You searched for: Author "Currier JR" Remove constraint Author: "Currier JR"
122 results on '"Currier JR"'

Search Results

3. The Pairing of Rapid Intensification Events and Eyewall Replacement Cycles in Tropical Cyclones in the Atlantic Basin from 2015 to 2020.

5. S011-05 OA. HLA-A*7401 is associated with protection from HIV-1 acquisition and disease progression in Mbeya, Tanzania

6. OA04-03. Characterization of cell-mediated immune responses generated by recombinant modified vaccinia Ankara (rMVA)-HIV-1 in a phase I vaccine trial

7. Two Lines to Carol

9. Harmonization guidelines for HLA-peptide multimer assays derived from results of a large scale international proficiency panel of the Cancer Vaccine Consortium

10. Protective Role of NS1-Specific Antibodies in the Immune Response to Dengue Virus Through Antibody-Dependent Cellular Cytotoxicity.

11. B cell receptor dependent enhancement of dengue virus infection.

12. Long term T cell response and safety of a tetravalent dengue vaccine in healthy children.

13. Efficacy and immunogenicity following dengue virus-1 human challenge after a tetravalent prime-boost dengue vaccine regimen: an open-label, phase 1 trial.

14. Low-dose dengue virus 3 human challenge model: a phase 1 open-label study.

15. Antibody targeting of conserved sites of vulnerability on the SARS-CoV-2 spike receptor-binding domain.

16. Diverse array of neutralizing antibodies elicited upon Spike Ferritin Nanoparticle vaccination in rhesus macaques.

17. Priming with Japanese encephalitis virus or yellow fever virus vaccination led to the recognition of multiple flaviviruses without boosting antibody responses induced by an inactivated Zika virus vaccine.

18. Humoral immune responses associated with control of SARS-CoV-2 breakthrough infections in a vaccinated US military population.

19. Soluble NS1 Antagonizes IgG- and IgA- Mediated Monocytic Phagocytosis of DENV Infected Cells.

20. SARS-CoV-2 spike-ferritin-nanoparticle adjuvanted with ALFQ induces long-lived plasma cells and cross-neutralizing antibodies.

21. Protection against SARS-CoV-2 Omicron BA.1 variant challenge in macaques by prime-boost vaccination with Ad26.COV2.S and SpFN.

22. Coronavirus Antibody Responses before COVID-19 Pandemic, Africa and Thailand.

23. Characterization of B-cell and T-cell responses to a tetravalent dengue purified inactivated vaccine in healthy adults.

24. Evolution of inflammation and immunity in a dengue virus 1 human infection model.

25. Dengue virus downregulates TNFR1- and TLR3-stimulated NF-κB activation by targeting RIPK1.

26. mRNA-1273 vaccination protects against SARS-CoV-2-elicited lung inflammation in nonhuman primates.

27. A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine Is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model.

28. A SARS-CoV-2 ferritin nanoparticle vaccine elicits protective immune responses in nonhuman primates.

29. SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity.

30. SARS-CoV-2 ferritin nanoparticle vaccine induces robust innate immune activity driving polyfunctional spike-specific T cell responses.

31. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.

32. Monomeric IgA Antagonizes IgG-Mediated Enhancement of DENV Infection.

33. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge.

34. Non-structural protein 1-specific antibodies directed against Zika virus in humans mediate antibody-dependent cellular cytotoxicity.

35. Efficacy and breadth of adjuvanted SARS-CoV-2 receptor-binding domain nanoparticle vaccine in macaques.

36. Stochastic Model of the Adaptive Immune Response Predicts Disease Severity and Captures Enhanced Cross-Reactivity in Natural Dengue Infections.

37. Longitudinal Analysis of Dengue Virus-Specific Memory T Cell Responses and Their Association With Clinical Outcome in Subsequent DENV Infection.

38. A SARS-CoV-2 spike ferritin nanoparticle vaccine protects against heterologous challenge with B.1.1.7 and B.1.351 virus variants in Syrian golden hamsters.

39. Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical Trial.

40. Enhanced dengue vaccine virus replication and neutralizing antibody responses in immune primed rhesus macaques.

41. Persistent COVID-19 Symptoms Minimally Impact the Development of SARS-CoV-2-Specific T Cell Immunity.

42. Efficacy of a Broadly Neutralizing SARS-CoV-2 Ferritin Nanoparticle Vaccine in Nonhuman Primates.

43. A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge Strain.

44. Temporally integrated single cell RNA sequencing analysis of PBMC from experimental and natural primary human DENV-1 infections.

45. Next-generation sequencing of 11 HLA loci in a large dengue vaccine cohort from the Philippines.

46. Safety and Immunogenicity of an AS03 B -Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized Study.

47. Analysis of cell-associated DENV RNA by oligo(dT) primed 5' capture scRNAseq.

48. Route of inoculation and mosquito vector exposure modulate dengue virus replication kinetics and immune responses in rhesus macaques.

49. Transcriptional and clonal characterization of B cell plasmablast diversity following primary and secondary natural DENV infection.

50. The Effects of Japanese Encephalitis Vaccine and Accelerated Dosing Scheduling on the Immunogenicity of the Chimeric Yellow Fever Derived Tetravalent Dengue Vaccine: A Phase II, Randomized, Open-Label, Single-Center Trial in Adults Aged 18 to 45 Years in the United States.

Catalog

Books, media, physical & digital resources